Aim: The aim of this study was to develop the Cancer Attitude Scale (CAS) and to evaluate its psychometric properties.
Methods: The study was conducted in a mixed-methods study. The preliminary version of the CAS was created by developing an item pool, and qualitative interviews. The items' content validity ratio was calculated to assess content validity. Construct validity was assessed using exploratory factor analysis and confirmatory factor analysis. Internal consistency and test-retest methods were used to determine the reliability of the scale. The Cancer Information Burden Scale was used to evaluate the convergent validity of the scale. Three hundred twenty-five healthy individuals selected by convenience sampling method were included in this study.
Results: The CAS sub-dimensions were determined as cancer diagnosis, cancer prevention, stigmatization of individuals with cancer, and personal empowerment after cancer. The content validity of the 22-item scale was 0.94 and four factors explaining 56% of the variance. The model fit indices were χ/df = 1.968, RMSEA = 0.055, SRMR = 0.085, and GFI = 0.904. . Cronbach's α and test-retest reliability coefficients of the total scale are 0.76 and 0.936, respectively. The CAS and Cancer Information Overload Scale showed acceptable convergent validity (r = 0.435, P < .001).
Conclusions: The Cancer Attitude Scale is a valid and reliable tool that can be applied to assess the attitudes of individuals in the community toward cancer in a multidimensional way.
Implications For Practice: Nurses play crucial roles in society, including enhancing cancer awareness, delivering counseling services, and providing health education. Cancer nursing should plan cancer awareness training in line with individuals' attitudes toward cancer and encourage positive attitudes that increase participation in screening programs.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.soncn.2024.151728 | DOI Listing |
J Oncol Pharm Pract
January 2025
Department of Pharmacy, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan.
Study Objective: Complex pharmacotherapy in cancer patients increases the likelihood of drug-drug interactions (DDIs). Pharmacists play a critical role in the identification and management of DDIs. The aim of present study was to evaluate the role of pharmacist in identifying antifungal drug interactions in cancer patients and providing relevant recommendations.
View Article and Find Full Text PDFRadiat Oncol
January 2025
German Cancer Consortium (DKTK), partner site Tübingen, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Background: For radiotherapy of head and neck cancer (HNC) magnetic resonance imaging (MRI) plays a pivotal role due to its high soft tissue contrast. Moreover, it offers the potential to acquire functional information through diffusion weighted imaging (DWI) with the potential to personalize treatment. The aim of this study was to acquire repetitive DWI during the course of online adaptive radiotherapy on an 1.
View Article and Find Full Text PDFBMC Pharmacol Toxicol
January 2025
Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Objective: Cyclin-dependent kinase (CDK)-4/6 inhibitors have significantly improved outcomes in several cancers but can also induce various organ system toxicities, including musculoskeletal disorders. This study aimed to comprehensively characterize the musculoskeletal adverse events (MSAEs) associated with CDK4/6 inhibitors based on real-world data.
Methods: Reports of MSAEs linked to CDK4/6 inhibitors from the first quarter (Q1) of 2015 and 2023 Q4 were extracted from the FAERS.
Exp Hematol Oncol
January 2025
Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Myelodysplastic Syndromes (MDS) represent a group of heterogeneous myeloid clonal diseases derived from aberrant hematopoietic stem/progenitor cells. Enhancer of zeste homolog 2 (EZH2) is an important regulator in gene expression through methyltransferase-dependent or methyltransferase-independent mechanisms. Herein, we found EZH2 inhibition led to MDS cell pyroptosis through RNA Helicase A (RHA) down-regulation induced overexpression of S100A9, a key regulator of inflammasome activation and pyroptosis.
View Article and Find Full Text PDFNeurol Res Pract
January 2025
Institute of Clinical Epidemiology and Biometry, Julius-Maximilians-Universität Würzburg (JMU), Haus D7, Josef-Schneider-Straße 2, 97080, Würzburg, Germany.
Background: Comprehensive clinical data regarding factors influencing the individual disease course of patients with movement disorders treated with deep brain stimulation might help to better understand disease progression and to develop individualized treatment approaches.
Methods: The clinical core data set was developed by a multidisciplinary working group within the German transregional collaborative research network ReTune. The development followed standardized methodology comprising review of available evidence, a consensus process and performance of the first phase of the study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!